These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28906325)

  • 1. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
    Gobbi G; Ghabrash MF; Nuñez N; Tabaka J; Di Sante J; Saint-Laurent M; Vida S; Kolivakis T; Low N; Cervantes P; Booij L; Comai S
    Int Clin Psychopharmacol; 2018 Jan; 33(1):34-43. PubMed ID: 28906325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study.
    Köhler S; Unger T; Hoffmann S; Steinacher B; Fydrich T; Bschor T
    Pharmacopsychiatry; 2013 Mar; 46(2):69-76. PubMed ID: 23093475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression.
    Hassan AK; Farmer KC; Brahm NC; Neas BR
    Int J Clin Pharm; 2016 Apr; 38(2):429-37. PubMed ID: 26935957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy.
    Kim-Romo DN; Rascati KL; Richards KM; Ford KC; Wilson JP; Beretvas SN
    J Manag Care Spec Pharm; 2016 May; 22(5):588-96. PubMed ID: 27123919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression.
    Ghabrash MF; Comai S; Tabaka J; Saint-Laurent M; Booij L; Gobbi G
    World J Biol Psychiatry; 2016; 17(2):165-70. PubMed ID: 26444701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.
    Kautzky A; Dold M; Bartova L; Spies M; Kranz GS; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Dikeos D; Rujescu D; Kasper S
    Acta Psychiatr Scand; 2019 Jan; 139(1):78-88. PubMed ID: 30291625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.
    Dold M; Bartova L; Mendlewicz J; Souery D; Serretti A; Porcelli S; Zohar J; Montgomery S; Kasper S
    Acta Psychiatr Scand; 2018 May; 137(5):401-412. PubMed ID: 29492960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression.
    Moderie C; Nuñez N; Fielding A; Comai S; Gobbi G
    Int J Neuropsychopharmacol; 2022 Jun; 25(6):479-488. PubMed ID: 35167671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
    Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D₆) as outcome measure.
    Østergaard SD; Bech P; Miskowiak KW
    J Affect Disord; 2016 Jan; 190():842-845. PubMed ID: 25487682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study.
    Tundo A; Betro' S; Iommi M; de Filippis R
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jan; 112():110425. PubMed ID: 34375683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.